Combined chemotherapy trials require combined pharmacogenetic approaches.
Steiner
Michael
M
Schuff-Werner
Peter
P
Freund
Mathias
M
Köhne
Claus-Henning
CH
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D009369:Neoplasms / Q000188:drug therapy; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics*; D011110:Polymorphism, Genetic; D011799:Quinazolines / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); C068874:raltitrexed; D002166:Camptothecin